MedTrace Logo

Examination of the Postprandial Bone Remodeling in Persons With Reduced GIP-Receptor Activity

NCT02518737 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2016-07-29

No results posted yet for this study

Summary

The bone tissue of the human adult body is in a constant process of break-down (resorption) and rebuilding (formation), a process called bone remodeling. The extent to which bone remodeling happens varies during the day, especially a decrease in the bone resorption is observed after eating.

The overall purpose of this study is to examine the possible role of the hormone Glucose-dependent Insulinotropic Polypeptide (GIP) in Bone Remodeling. GIP is released from cells in the gut after eating, and previous studies have shown an effect of GIP on bone tissue. In addition, it has been observed that the risk of bone fracture is 60% higher in women with a mutation in the GIP receptor, when compared to women with a normal functioning GIP receptor.

In the present study humans with a mutation in their GIP receptor is compared to humans with a normal functioning GIP receptor. The study population will be examined during a meal stimulation test, where blood will be sampled regularly. The blood samples will be examined for markers of bone resorption among other markers of bone remodeling, GIP and other gut hormones.

The hypothesis for the present study is that GIP secreted after meal ingestion inhibits bone resorption. Thus it is expected that the decrease in resorption is less pronounced in the humans carrying the GIP-receptor mutation, compared to humans with a normal functioning GIP receptor.

Conditions

  • Bone Remodeling

Interventions

OTHER

Meal Test

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Glostrup University Hospital, Copenhagen

    collaborator OTHER

  • The Novo Nordisk Foundation Center for Basic Metabolic Research

    collaborator OTHER

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Bolette Hartmann, PhD · University of Copenhagen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02518737 on ClinicalTrials.gov